Thioredoxin interacting protein (TXNIP) as regulator of vascular function
AssigneeUniversity of Rochester
InventorBradford C. Berk
Life of this patent
Estimating the term…
Abstract
The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF-ASK1-JNK-p38 pathways.
Claims9
A method of treating a vascular disease characterized by reduced laminar flow in a subject comprising:
- selecting a subject having a vascular disease characterized by reduced laminar flow;
- and
- administering to the selected subject a therapeutically effective amount of a nucleic acid molecule that inhibits expression of thioredoxin interacting protein (TXNIP) under conditions effective to inhibit expression of TXNIP in endothelial or vascular smooth muscle cells, thereby treating the vascular disease characterized by reduced laminar flow.
A method of treating a vascular disease condition in a subject comprising:
- providing an siRNA molecule that is targeted to SEQ ID NO:
- 1 and inhibits expression of thioredoxin interacting protein (TXNIP);
- and
- administering a therapeutically effective amount of the siRNA molecule to a subject under conditions effective to inhibit expression of TXNIP in endothelial or vascular smooth muscle cells, thereby treating the vascular disease condition.
A method of treating a vascular disease characterized by reduced laminar flow in a subject comprising:
- selecting a subject having a vascular disease characterized by reduced laminar flow which is selected from the group consisting of atherosclerosis, coronary artery disease, cardiovascular disease, hypertension, peripheral vascular disease, diabetes, and sepsis;
- and
- administering to the selected subject a therapeutically effective amount of a nucleic acid molecule that inhibits expression of thioredoxin interacting protein (TXNIP) under conditions effective to inhibit expression of TXNIP in endothelial or vascular smooth muscle cells, thereby treating the vascular disease characterized by reduced laminar flow.
Dependencies are inferred from the claim text.